Kenvue Shares Rebound Amidst Controversy: Reuters Report

Kenvue Inc., the maker of Tylenol, saw its shares rebound by 6% after reaching a record low, as reported by Reuters. This recovery followed comments made by former President Donald Trump linking Tylenol to autism. Analysts attribute the stock price increase to the absence of credible scientific evidence supporting Trump's claims. Kenvue, which was recently spun off from Johnson & Johnson, has reaffirmed that there is no scientifically established link between acetaminophen, the active ingredient in Tylenol, and autism. Prior to Trump's remarks, Kenvue's shares had fallen to an all-time low. Tylenol generates approximately $1 billion in annual revenue for Kenvue, according to Morningstar estimates. While Citi analysts anticipate limited legal risk for the company, they acknowledge the potential for a decline in consumer demand due to negative publicity.